Medco Health Solutions
on Thursday completed its acquisition of
United BioSource Corporation
in an all-cash transaction valued at approximately $730 million, creating a complementary and comprehensive research organization that extends Medco's core capabilities in data analytics and research to accelerate pharmaceutical knowledge.
UBC is now a wholly-owned subsidiary of Medco that will run independently from Medco's core business to ensure compliance with contractual requirements and client expectations. Dr. Robert S. Epstein, Medco's chief medical officer and president of the Medco Research Institute™, will have overall responsibility for the UBC business. UBC Chief Executive Officer Ethan Leder will continue in his position, overseeing the company's current operations.
The transaction was funded with the proceeds of Medco's recently completed senior notes offering. The new business is expected to be slightly accretive to Medco shareholders in 2011, excluding one-time items and amortization.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.